Literature DB >> 22373559

Disruption of NMDAR-CRMP-2 signaling protects against focal cerebral ischemic damage in the rat middle cerebral artery occlusion model.

Joel M Brittain1, Rui Pan, Haitao You, Tatiana Brustovetsky, Nickolay Brustovetsky, Gerald W Zamponi, Wei-Hua Lee, Rajesh Khanna.   

Abstract

Collapsin response mediator protein 2 (CRMP-2), traditionally viewed as an axon/dendrite specification and axonal growth protein, has emerged as nidus in regulation of both pre- and post-synaptic Ca ( 2+) channels. Building on our discovery of the interaction and regulation of Ca ( 2+) channels by CRMP-2, we recently identified a short sequence in CRMP-2 which, when appended to the transduction domain of HIV TAT protein, suppressed acute, inflammatory and neuropathic pain in vivo by functionally uncoupling CRMP-2 from the Ca ( 2+) channel. Remarkably, we also found that this region attenuated Ca ( 2+) influx via N-methylD-Aspartate receptors (NMDARs) and reduced neuronal death in a moderate controlled cortical impact model of traumatic brain injury (TBI). Here, we sought to extend these findings by examining additional neuroprotective effects of this peptide (TAT-CBD3) and exploring the biochemical mechanisms by which TAT-CBD3 targets NMDARs. We observed that an intraperitoneal injection of TAT-CBD3 peptide significantly reduced infarct volume in an animal model of focal cerebral ischemia. Neuroprotection was observed when TAT-CBD3 peptide was given either prior to or after occlusion but just prior to reperfusion. Surprisingly, a direct biochemical complex was not resolvable between the NMDAR subunit NR2B and CRMP-2. Intracellular application of TAT-CBD3 failed to inhibit NMDAR current. NR2B interactions with the post synaptic density protein 95 (PSD-95) remained intact and were not disrupted by TAT-CBD3. Peptide tiling of intracellular regions of NR2B revealed two 15-mer sequences, in the carboxyl-terminus of NR2B, that may confer binding between NR2B and CRMP-2 which supports CRMP-2's role in excitotoxicity and neuroprotection.

Entities:  

Keywords:  CRMP-2; MCAO model; N-methylD-aspartate receptor; focal cerebral ischemia; peptide

Mesh:

Substances:

Year:  2012        PMID: 22373559      PMCID: PMC3367672          DOI: 10.4161/chan.18919

Source DB:  PubMed          Journal:  Channels (Austin)        ISSN: 1933-6950            Impact factor:   2.581


  42 in total

1.  Calpain-mediated collapsin response mediator protein-1, -2, and -4 proteolysis after neurotoxic and traumatic brain injury.

Authors:  Zhiqun Zhang; Andrew K Ottens; Shankar Sadasivan; Firas H Kobeissy; Tie Fang; Ronald L Hayes; Kevin K W Wang
Journal:  J Neurotrauma       Date:  2007-03       Impact factor: 5.269

Review 2.  Polymodal regulation of NMDA receptor channels.

Authors:  Anna Kloda; Boris Martinac; David J Adams
Journal:  Channels (Austin)       Date:  2007-09-13       Impact factor: 2.581

3.  Selective blockade of N-type voltage-sensitive calcium channels protects against brain injury after transient focal cerebral ischemia in rats.

Authors:  S S Bowersox; T Singh; R R Luther
Journal:  Brain Res       Date:  1997-02-07       Impact factor: 3.252

4.  Proteomic analysis of cPKCβII-interacting proteins involved in HPC-induced neuroprotection against cerebral ischemia of mice.

Authors:  Xiangning Bu; Nan Zhang; Xuan Yang; Yanyan Liu; Jianli Du; Jing Liang; Qunyuan Xu; Junfa Li
Journal:  J Neurochem       Date:  2011-03-01       Impact factor: 5.372

Review 5.  Glutamate-based therapeutic approaches: clinical trials with NMDA antagonists.

Authors:  Keith W Muir
Journal:  Curr Opin Pharmacol       Date:  2005-12-15       Impact factor: 5.547

6.  The role of excitatory amino acids and NMDA receptors in traumatic brain injury.

Authors:  A I Faden; P Demediuk; S S Panter; R Vink
Journal:  Science       Date:  1989-05-19       Impact factor: 47.728

Review 7.  Targeting neuroprotection as an alternative approach to preventing and treating neuropathic pain.

Authors:  Thierry Bordet; Rebecca M Pruss
Journal:  Neurotherapeutics       Date:  2009-10       Impact factor: 7.620

8.  Neuroprotection in the rat lateral fluid percussion model of traumatic brain injury by SNX-185, an N-type voltage-gated calcium channel blocker.

Authors:  Lillian L Lee; Ethel Galo; Bruce G Lyeth; J Paul Muizelaar; Robert F Berman
Journal:  Exp Neurol       Date:  2004-11       Impact factor: 5.330

9.  The glutamate antagonist MK-801 reduces focal ischemic brain damage in the rat.

Authors:  C K Park; D G Nehls; D I Graham; G M Teasdale; J McCulloch
Journal:  Ann Neurol       Date:  1988-10       Impact factor: 10.422

Review 10.  The CRMP family of proteins and their role in Sema3A signaling.

Authors:  Eric F Schmidt; Stephen M Strittmatter
Journal:  Adv Exp Med Biol       Date:  2007       Impact factor: 2.622

View more
  18 in total

1.  AAV-encoded CaV2.2 peptide aptamer CBD3A6K for primary sensory neuron-targeted treatment of established neuropathic pain.

Authors:  Hongwei Yu; Seung Min Shin; Hongfei Xiang; Dongman Chao; Yongsong Cai; Hao Xu; Rajesh Khanna; Bin Pan; Quinn H Hogan
Journal:  Gene Ther       Date:  2019-05-22       Impact factor: 5.250

2.  Homology-guided mutational analysis reveals the functional requirements for antinociceptive specificity of collapsin response mediator protein 2-derived peptides.

Authors:  Aubin Moutal; Wennan Li; Yue Wang; Weina Ju; Shizhen Luo; Song Cai; Liberty François-Moutal; Samantha Perez-Miller; Jackie Hu; Erik T Dustrude; Todd W Vanderah; Vijay Gokhale; May Khanna; Rajesh Khanna
Journal:  Br J Pharmacol       Date:  2017-03-17       Impact factor: 8.739

3.  Lanthionine Ketimine Ethyl Ester Accelerates Remyelination in a Mouse Model of Multiple Sclerosis.

Authors:  Jeffrey L Dupree; Pablo M Paez; Seema K Tiwari-Woodruff; Travis T Denton; Kenneth Hensley; Christina G Angeliu; Anne I Boullerne; Sergey Kalinin; Sophia Egge; Veronica T Cheli; Giancarlo Denaroso; Kelley C Atkinson; Micah Feri; Douglas L Feinstein
Journal:  ASN Neuro       Date:  2022 Jan-Dec       Impact factor: 5.200

4.  Suppression of pain-related behavior in two distinct rodent models of peripheral neuropathy by a homopolyarginine-conjugated CRMP2 peptide.

Authors:  Weina Ju; Qi Li; Yohance M Allette; Matthew S Ripsch; Fletcher A White; Rajesh Khanna
Journal:  J Neurochem       Date:  2013-01-20       Impact factor: 5.372

Review 5.  Collapsin Response Mediator Proteins: Novel Targets for Alzheimer's Disease.

Authors:  Tam T Quach; Aubin Moutal; Rajesh Khanna; Nicholas P Deems; Anne-Marie Duchemin; Ruth M Barrientos
Journal:  J Alzheimers Dis       Date:  2020       Impact factor: 4.472

Review 6.  Specific binding of lacosamide to collapsin response mediator protein 2 (CRMP2) and direct impairment of its canonical function: implications for the therapeutic potential of lacosamide.

Authors:  Sarah M Wilson; Rajesh Khanna
Journal:  Mol Neurobiol       Date:  2014-06-20       Impact factor: 5.590

7.  Opening Pandora's jar: a primer on the putative roles of CRMP2 in a panoply of neurodegenerative, sensory and motor neuron, and central disorders.

Authors:  Rajesh Khanna; Sarah M Wilson; Joel M Brittain; Jill Weimer; Rukhsana Sultana; Allan Butterfield; Kenneth Hensley
Journal:  Future Neurol       Date:  2012-11-01

8.  SUMOylation alters CRMP2 regulation of calcium influx in sensory neurons.

Authors:  Weina Ju; Qi Li; Sarah M Wilson; Joel M Brittain; Louay Meroueh; Rajesh Khanna
Journal:  Channels (Austin)       Date:  2013-03-19       Impact factor: 2.581

9.  Differential regulation of collapsin response mediator protein 2 (CRMP2) phosphorylation by GSK3ß and CDK5 following traumatic brain injury.

Authors:  Sarah M Wilson; Seul Ki Yeon; Xiao-Fang Yang; Ki Duk Park; Rajesh Khanna
Journal:  Front Cell Neurosci       Date:  2014-05-28       Impact factor: 5.505

10.  Differential neuroprotective potential of CRMP2 peptide aptamers conjugated to cationic, hydrophobic, and amphipathic cell penetrating peptides.

Authors:  Aubin Moutal; Liberty François-Moutal; Joel M Brittain; May Khanna; Rajesh Khanna
Journal:  Front Cell Neurosci       Date:  2015-01-26       Impact factor: 5.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.